article thumbnail

Treatment paradigm shifting for men with prostate cancer

AuntMinnie

New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. I can’t emphasize that enough.

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

year over year, according to the newly published IMV 2024 PET Market Summary Report. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging. IMV's 2024 PET Market Summary Report explores market trends in U.S.

PET Scan 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging. However, few freestanding theranostics centers exist today. Hope added.

article thumbnail

Sgouros honored with SNMMI's Paul C. Aebersold award

AuntMinnie

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has bestowed its Paul C. Aebersold Award for outstanding achievement in basic nuclear medicine science on George Sgouros, PhD, of Johns Hopkins Medicine in Baltimore. George Sgouros, PhD, of Johns Hopkins Medicine in Baltimore.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

article thumbnail

SNMMI: Y-90-FAPI-46 more effective for advanced sarcoma

AuntMinnie

An emerging radioligand therapy could be particularly effective for controlling advanced sarcoma compared to other cancers, according to research presented June 8 in a Young Investigator Award session at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Toronto.